According to filings with the U.S. Securities and Exchange Commission, AgNovos Bioscience is raising $60,000,000.00 in new funding. Sources indicate that as part of senior management Director, James Barry played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About AgNovos Bioscience
AgNovos Biocience is a developer of new therapies that leverage proprietary, bone-building technology and regenerative medicine to address unmet needs in the treatment of bone disease. The Companys first product, the OSSURE Local Osteo-Enhancement Procedure (LOEP) kit has been evaluated in multiple clinical studies and is available in select markets. The Company has initiated RESTORE, a randomized, controlled, prospective, single-blinded, multi-national study designed to evaluate the impact of OSSURE LOEP on the risk of secondary hip fractures. RESTORE is one of the largest prospective studies ever conducted in orthopedic traumatology. The data generated will be critical to gaining access to new markets, including the U.S. and Japan. The Company has also developed the AGN1 LOEP SV kit investigational device intended to treat stable but painful vertebral compression fractures. That device has received both a Breakthrough Device designation and an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration. AgNovos Bioscience is privately held and has its corporate headquarters in New York City with manufacturing, research & development, and corporate support services located in Rockville, MD.

To learn more about AgNovos Bioscience, visit http://www.agnovos.com/

Contact:
James Barry, Director
609-319-2664

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.